BRIEF-Pharnext: Financing Agreement With Néovacs For EUR 20.7 Mln Net To Further Develop PXT3003
Oct 3 (Reuters) - Pharnext SA : * PHARNEXT EXECUTES A FINANCING AGREEMENT WITH NÉOVACS FOR EUR 20.7 MILLION NET TO FURTHER DEVELOP PXT3003 FOR CHARCOT-MARIE-TOOTH DISEASE TYPE 1A * CUMULATIVE FINANCING RESULTING FROM THESE AGREEMENTS BRINGS A TOTAL POTENTIALLY AVAILABLE NET AMOUNT OF APPROXIMATELY EUR 46.7 MILLION * SUBJECT TO EACH PARTY'S SATISFYING ITS OBLIGATIONS, CONSIDERS IT WOULD BE ABLE TO FINANCE ITS OPERATIONS, PREMIER TRIAL UNTIL Q1 2024
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.